Conv. Plasma
Nigella Sativa

All ivermectin studies
Meta analysis
study COVID-19 treatment researchIvermectinIvermectin (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Platform Randomised trial of INterventions against COVID-19 In older peoPLE (PRINCIPLE): protocol for a randomised, controlled, open-label, adaptive platform, trial of community treatment of COVID-19 syndromic illness in people at higher risk

Jun 2021  
  Source   PDF   All Studies   Meta AnalysisMeta
Ivermectin for COVID-19
4th treatment shown to reduce risk in August 2020
*, now known with p < 0.00000000001 from 102 studies, recognized in 22 countries.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
4,000+ studies for 60+ treatments.
Protocol paper for the PRINCIPLE trial. For the colchicine arm see Dorward, for budesonide see Yu, and for ivermectin see Hayward.
Study covers ivermectin, budesonide, and colchicine.
Hayward et al., 18 Jun 2021, peer-reviewed, 26 authors, trial ISRCTN86534580.
This PaperIvermectinAll
Platform Randomised trial of INterventions against COVID-19 In older peoPLE (PRINCIPLE): protocol for a randomised, controlled, open-label, adaptive platform, trial of community treatment of COVID-19 syndromic illness in people at higher risk
Gail Hayward, Professor Christopher C Butler, Ly-Mee Yu, Benjamin R Saville, Nicholas Berry, Jienchi Dorward, Oghenekome Gbinigie, Oliver Van Hecke, Emma Ogburn, Hannah Swayze, Emily Bongard, Julie Allen, Sharon Tonner, Heather Rutter, Sarah Tonkin-Crine, Aleksandra Borek, David Judge, Jenna Grabey, Simon De Lusignan, Nicholas P B Thomas, Philip H Evans, Monique I Andersson, Martin Llewelyn, Mahendra Patel, Susan Hopkins, F D Richard Hobbs
BMJ Open, doi:10.1136/bmjopen-2020-046799
Introduction There is an urgent need to idenfy treatments for COVID-19 that reduce illness duration and hospital admission in those at higher risk of a longer illness course and complications. Methods and analysis The Platform Randomised trial of INterventions against COVID-19 In older peoPLE trial is an open-label, multiarm, prospective, adaptive platform, randomised clinical trial to evaluate potential treatments for COVID-19 in the community. A master protocol governs the addition of new interventions as they become available, as well as the inclusion and cessation of existing intervention arms via frequent interim analyses. The first three interventions are hydroxychloroquine, azithromycin and doxycycline. Eligible participants must be symptomatic in the community with possible or confirmed COVID-19 that started in the preceding 14 days and either (1) aged 65 years and over or (2) aged 50-64 years with comorbidities. Recruitment is through general practice, health service helplines, COVID-19 'hot hubs' and directly through the trial website. Participants are randomised to receive either usual care or a study drug plus usual care, and outcomes are collected via daily online symptom diary for 28 days from randomisation. The research team contacts participants and/or their study partner following days 7, 14 and 28 if the online diary is not completed. The trial has two coprimary endpoints: time to first self-report of feeling recovered from possible COVID-19 and hospital admission or death from possible COVID-19 infection, both within 28 days from randomisation. Prespecified interim analyses assess efficacy or futility of interventions and to modify randomisation probabilities that allocate more participants to interventions with better outcomes.
Anand, Bradley, Fool's gold? Why blinded trials are not always best, BMJ, doi:10.1136/bmj.l6228
Angus, white@ covid19crc. org. Global coalition to accelerate COVID-19 clinical research in resource-limited settings, Lancet, doi:10.1016/S0140-6736(20)30798-4
Baden, Rubin, Covid-19 -The Search for Effective Therapy, N Engl J Med, doi:10.1056/NEJMe2005477
Berry, Connor, Lewis, The platform trial: an efficient strategy for evaluating multiple treatments, JAMA, doi:10.1001/jama.2015.2316
Burgess, Gill, Rising numbers of positive covid-19 tests in the UK, BMJ, doi:10.1136/bmj.m3605
Butler, Connor, Lewis, Answering patient-centred questions efficiently: response-adaptive platform trials in primary care, Br J Gen Pract, doi:10.3399/bjgp18X696569
Butler, Van Der Velden, Bongard, Oseltamivir plus usual care versus usual care for influenza-like illness in primary care: an open-label, pragmatic, randomised controlled trial, The Lancet, doi:10.1016/S0140-6736(19)32982-4
De Lusignan, Jones, Dorward, The Oxford Royal College of general practitioners clinical informatics digital hub: protocol to develop extended COVID-19 surveillance and trial platforms, JMIR Public Health Surveill, doi:10.2196/19773
Dobson, Whitley, Pocock, Oseltamivir treatment for influenza in adults: a meta-analysis of randomised controlled trials, Lancet, doi:10.1016/S0140-6736(14)62449-1
Docherty, Harrison, Green, Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study, BMJ
Dong, Du, Gardner, An interactive web-based dashboard to track COVID-19 in real time, Lancet Infect Dis, doi:10.1016/S1473-3099(20)30120-1
Ford, Pragmatic trials, N Engl J Med, doi:10.1056/NEJMra1510059
Horby, Randomised evaluation of COVID-19 therapy (RECOVERY)
Jefferson, Jones, Doshi, Oseltamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments, BMJ, doi:10.1136/bmj.g2545
Kim, Read, Fauci, Therapy for early COVID-19: a critical need, JAMA, doi:10.1001/jama.2020.22813
Leventhal, Phillips, Burns, The Common-Sense model of self-regulation (CSM): a dynamic framework for understanding illness self-management, J Behav Med, doi:10.1007/s10865-016-9782-2
Livingston, Bucher, Coronavirus disease 2019 (COVID-19) in Italy, JAMA, doi:10.1001/jama.2020.4344
Mitjo, Monné, Ubals, Hydroxychloroquine for early treatment of adults with mild coronavirus disease 2019: a randomized, controlled trial, Clin Infect Dis, doi:10.1093/cid/ciaa1009
Moustgaard, Clayton, Jones, Impact of blinding on estimated treatment effects in randomised clinical trials: metaepidemiological study, BMJ, doi:10.1136/bmj.l6802
Skipper, Pastick, Engen, Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19 : A Randomized Trial, Ann Intern Med, doi:10.7326/M20-4207
Thorpe, Zwarenstein, Oxman, A pragmaticexplanatory continuum indicator summary (Precis): a tool to help trial designers, J Clin Epidemiol, doi:10.1016/j.jclinepi.2008.12.011
Topp, Østergaard, Søndergaard, The WHO-5 well-being index: a systematic review of the literature, Psychother Psychosom, doi:10.1159/000376585
Woodcock, Lavange, Master protocols to study multiple therapies, multiple diseases, or both, N Engl J Med, doi:10.1056/NEJMra1510062
Wu, Mcgoogan, Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention, JAMA, doi:10.1001/jama.2020.2648
Zhou, Yu, Du, Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study, Lancet, doi:10.1016/S0140-6736(20)30566-3
Zuidgeest, Goetz, Groenwold, Series: pragmatic trials and real world evidence: paper 1. Introduction, J Clin Epidemiol, doi:10.1016/j.jclinepi.2016.12.023
Zuidgeest, Welsing, Van Thiel, Series: pragmatic trials and real world evidence: paper 5. usual care and real life comparators, J Clin Epidemiol, doi:10.1016/j.jclinepi.2017.07.001
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop